Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenibPhilippe Saïag, Caroline Dutriaux, Caroline Robert et al.|European Journal of Cancer|2021Cited by 13
An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastasesCaroline Dutriaux, Philippe Saïag, O. Dereure et al.|European Journal of Cancer|2022Cited by 13
Differential gradients of immunotherapy vs targeted therapy efficacy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MelBase)David Russo, Lise Boussemart, Stéphane Dalle et al.|Frontiers in Oncology|2023Cited by 10
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational studyS. Monestier, Stéphane Dalle, Laurent Mortier et al.|International Journal of Cancer|2021Cited by 9
Late-onset adverse events of anti-PD1 therapy in melanoma patients: An observational study from MELBASE, a nationwide prospective cohortClémentine Carlet, Charlée Nardin, Stéphane Dalle et al.|Journal of the American Academy of Dermatology|2021Cited by 9